
|Articles|July 18, 2007
- Pharmaceutical Executive-07-18-2007
- Volume 0
- Issue 0
Forecasting DTC's Future
Spending expected to increase mildly in the short term
Advertisement
And now, the climate report--the climate for direct-to-consumer advertising, that is. Conditions should be mildly favorable in the coming year, with a lot of focus on electronic communication and patient education. Government regulation will continue to present the industry's cloudiest weather.
The predictions come courtesy of last week's Annual DTC Industry Check Up, a survey conducted each year since 2002 by Cegedim Dendrite. The survey included 134 respondents, from manufacturers, consultants, agencies, and other vendors. DTC's outlook for the coming year, according to respondents:
- The big challenge to DTC is perceived to be government regulation, which was mentioned by 60 percent of respondents, up from 50 percent last year. Other leading challenges included effective measurement (say 35 percent of respondents), physician backlash (34 percent), declining effectiveness of DTC (32 percent), and consumer backlash (31 percent). Consumer backlash dropped 13 percentage points since last year--pushing it from second place on the list to fifth.
- There is a bit of a sunny forecast for DTC: Nearly half the respondents expected spending to be up next year--though only about a quarter expected growth to top 5 percent.
- Use of electronic media is expected to increase next year. Leading the list of areas in which respondents expect more spending are Web sites, search engine marketing, doctors' office programs, e-mail, and pharmacy programs.
- Health Care Provider (HCP) programs are a big area of focus, with 88 percent of respondents reporting that they use some form of HCP program to augment DTC (compared with 73 percent in 2006). The biggest area is HCP materials distributed by the sales force--a tactic used by 79 percent of respondents.
The full white paper is available at www.dendrite.com.
Articles in this issue
about 19 years ago
The Oprah MomentAdvertisement
Related to this article

Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.

AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.

Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.

Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.

FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.

Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.

FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on PharmExec
1
Understanding the Latest with MFN Pricing and What It Means to Pharma
2
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5

